gv1001 + granulocyte-macrophage colony-stimulating factor

GV1001 + granulocyte-macrophage colony-stimulating factor is a combination of a peptide vaccine and a cytokine immunomodulator used primarily in oncologic and neurodegenerative indications in a therapeutic context. **GV1001** is a 16-amino acid peptide derived from the catalytic subunit of human telomerase reverse transcriptase (hTERT), designed to elicit an immune response against cancer cells by presenting a widely expressed tumor-associated antigen[3][7]. It has also demonstrated neuroprotective effects, with research indicating reduction in tau pathology and beneficial effects in diseases such as Alzheimer's disease and progressive supranuclear palsy (PSP)[1][5]. **Granulocyte-macrophage colony-stimulating factor (GM-CSF)** is a recombinant glycoprotein that stimulates proliferation and differentiation of granulocytes and macrophages, enhancing host defense, particularly after myelosuppressive therapy and in stem cell mobilization[4][8][10]. In this combination, GM-CSF acts as an immunological adjuvant to the GV1001 peptide vaccine, augmenting the immune response.

Brand names

Riavax

Other names

telomerase peptide vaccine + GM-CSF